来自大肠杆菌的全长重组抗体:生产、表征、效应功能(Fc)工程化与临床评价
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
46.9分
★★★☆☆
站内排序·非疗效
ALL SOURCES
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses.
合适的生物标志物选择将改善接受 ICI 治疗的 NSCLC 患者的治疗结局,尤其是在联合 ICI 治疗的情况下。
PDL-1 expression in lung carcinoma and its correlation with clinicopathological and prognostic characteristics.
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。